Non-small cell lung cancer · line 2 · Zenocutuzumab monotherapy (eNRGy) — NRG1-fusion+ NSCLC (pan-tumor activity)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-ZENOCUTUZUMAB-NRG1-NSCLC |
| ID | IND-NSCLC-NRG1-ZENOCUTUZUMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track for NRG1 fusion+ metastatic NSCLC; FDA-approved 2024-12 for NSCLC + pancreatic adenocarcinoma. eNRGy primary-trial source stub not yet in KB — citation flagged in commit body for source-ingest follow-up.
Used By
No reverse references found in the YAML corpus.